Loading...
Docoh

Thu. 9 Jun 2022, 6:02pm ET Benzinga Movers

Gainers

  • Reshape Lifesciences (NASDAQ:RSLS) shares rose 9.4% to $0.81 during Thursday's after-market session. The market value of their outstanding shares is at $2.8 million.
  • PolarityTE (NASDAQ:PTE) stock rose 8.98% to $2.79. The market value of their outstanding shares is at $11.2 million.
  • PhaseBio Pharmaceuticals (NASDAQ:PHAS) stock increased by 7.9% to $0.8. The company's market cap stands at $38.9 million.
  • BeyondSpring (NASDAQ:BYSI) shares rose 5.84% to $1.81. The company's market cap stands at $70.4 million.
  • Abeona Therapeutics (NASDAQ:ABEO) stock rose 5.58% to $0.18. The company's market cap stands at $26.3 million.
  • Precision BioSciences (NASDAQ:DTIL) shares rose 5.51% to $1.53. The company's market cap stands at $95.1 million.

Losers

  • Cidara Therapeutics (NASDAQ:CDTX) shares decreased by 6.8% to $0.55 during Thursday's after-market session. The market value of their outstanding shares is at $37.9 million.
  • Illumina (NASDAQ:ILMN) shares declined by 6.45% to $210.0. Today's trading volume for this security ended up closing at 60.9K shares, which is 6.0 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $32.9 billion.
  • Kiora Pharmaceuticals (NASDAQ:KPRX) stock decreased by 5.56% to $0.41. At the close, Kiora Pharmaceuticals's trading volume reached 72.1K shares. This is 18.8% of its average volume over the last 100 days. The market value of their outstanding shares is at $5.1 million.
  • Finch Therapeutics Group (NASDAQ:FNCH) shares fell 5.31% to $2.68. The market value of their outstanding shares is at $127.4 million.
  • Kiromic BioPharma (NASDAQ:KRBP) shares fell 5.01% to $0.5. The market value of their outstanding shares is at $7.8 million.
  • Spruce Biosciences (NASDAQ:SPRB) stock declined by 4.92% to $1.74. The market value of their outstanding shares is at $40.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.